CD ComputaBio Has Launched Hybrid Method for Virtual Screening Service to Assist Scientists
Earlier this month, CD ComputaBio, a senior US provider of computational biology services, announced that it had expanded its service line by providing hybrid method for virtual screening service to customers around the world. Since its establishment, CD ComputaBio has been committed to providing high-quality and all-round services for scientists and researchers to help them make rapid breakthroughs in drug design and clinical drug research.
Based on computer simulation technology, virtual screening (VS) can search libraries of small molecules to identify the small-molecule compounds that are most likely to combine with drug targets. Since the hit rate of virtual screening can reach 2%-24%, much higher than that of traditional screening methods, this technology has become an essential tool in drug design.
Hybrid method for virtual screening is an integrated VS method which depends on both structural similarity and ligand similarity. With evolution-based ligand-binding information, the hybrid method can predict small-molecule binders more efficiently. At the same time, this method also integrates two other similarities, global structural similarity and pocket similarity, which further ensures the accuracy of the screening results, and enables the researchers to quickly obtain the lead compounds that best meets their expectations from dozens or even millions of molecules.
CD ComputaBio has always been devoted to helping researchers to strike a balance between the cost and the results of research. In the hybrid virtual screening provided by the company, the structural and ligand information is combined into a standalone method, which can help experimenters make full use of all available chemical and biological information, thus overcoming the shortcomings of traditional screening methods, such as great consumption of time and labor and high false negative.
“We provide different strategies to integrate virtual screening methods based on ligands and structures, which can be roughly divided into three types, hierarchical, parallel and hybrid methods,” introduces a senior scientist from CD ComputaBio who has been engaged in drug design for many years. “According to the different requirements of researchers, we can adopt corresponding strategies to screen and obtain more relevant and specific compounds. These hybrid approaches undoubtedly give scientists and researchers more choices and will make drug preparation and discovery more flexible and effective as well.”
Related services provided by CD ComputaBio include 3D-QSAR, Reverse Virtual Screening and so on. All of them now are easily accessible on the website: https://www.computabio.com/
About CD ComputaBio
As a senior service provider in the pharmaceutical field in the United States, CD ComputaBio has always kept its original aspiration to provide high-quality professional services to scientists and researchers engaged in drug discovery and design. At present, the company’s services have covered Molecular Dynamics Simulation Service, Protein Structure Modeling Service, Molecular Docking Service and other fields.
-
Most popular related searches
Customer comments
No comments were found for CD ComputaBio Has Launched Hybrid Method for Virtual Screening Service to Assist Scientists. Be the first to comment!